NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- Achillion
Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and
development of small molecule drugs to combat the most challenging
infectious diseases, today announced that Michael D. Kishbauch, Chief
Executive Officer of Achillion, will be presenting a corporate overview and
update on the Company's clinical programs in HIV, HCV and serious bacterial
infections at the following upcoming investment conferences:
-- SIGnificant Investment Options in Healthcare by Susquehanna Financial
Group -- March 1, 2007 at 1:30 PM at the Omni Berkshire Place Hotel in
New York City;
-- Cowen and Company Annual Healthcare Conference -- March 13, 2007 at
8:00 AM at the Marriott Copley Place in Boston.
In addition, Achillion senior scientists will participate in the
following panel discussions during the SIGnificant Investment Options in
Healthcare conference:
-- John Pottage, M.D., Chief Medical Officer, will participate in a panel
discussion at 8:00 AM entitled, "Antibiotic Resistance:
Challenges/Opportunities in MRSA, C. difficile, and S. pneumonia";
-- Milind S. Deshpande, Ph.D., Achillion's Chief Scientific Officer, will
participate in a panel discussion at 10:00 AM entitled, "Hepatitis C
Virus: What to Target -- Proteases, Polymerases or Replicases?"
About Achillion
Achillion is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative treatments for infectious
diseases. Achillion is currently developing treatments for HIV infection,
chronic hepatitis C infection and serious hospital-based bacterial
infections. For more information on Achillion Pharmaceuticals, please visit
the company's web site at http://www.achillion.com or call Achillion at
1-203-624-7000. ACHN-G
Contact: Media:
Mary Kay Fenton Kari Watson
Achillion Pharmaceuticals, Inc. MacDougall Biomedical Communications
Tel. (203) 624-7000 Tel. (508) 647-0209
mfenton@achillion.com kwatson@macbiocom.com
SOURCE Achillion Pharmaceuticals, Inc.
 back to top
Related links:
http://www.achillion.com
CONTACT:
Mary Kay Fenton of Achillion Pharmaceuticals,
Inc., +1-203-624-7000, or mfenton@achillion.com; or Kari Watson
of MacDougall Biomedical Communications, +1-508-647-0209, or
kwatson@macbiocom.com, for Achillion Pharmaceuticals, Inc.
|
